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Background: The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are
not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies
whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this
metaanalysis, we aimed to compare the efficacy of frovatriptan versus rizatriptan, zolmitriptan, and almotriptan.
Methods: Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design.
Patients were asked to treat three consecutive migraine attacks with frovatriptan 2.5 mg and three consecutive
migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg).
Results: In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean
headache intensity after 2 hours was 1.2 +/- 1.0 for frovatriptan and 1.6 +/- 1.0 for the other triptans (p<0.05); all
triptans showed significant improvement of headache. Frovatriptan resulted in significantly lower relapse rates at 24
hours and 48 hours when taken in migraine attacks with aura.
Conclusions: Our data suggest that frovatriptan is efficacious and even superior in some endpoints also when
taken during the headache phase in migraine attacks with aura. This is of particular importance for those many
patients who have migraine attacks both without and with aura.
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The efficacy of triptans in migraine with aura refers to
different questions. First, it is of interest whether trip-
tans are able to treat the aura symptoms [1]. Second, it
has been studied whether triptans taken during the aura
phase of a migraine attack are efficacious to treat the
headache [1-4], which is not recommended in treatment
guidelines [5]. Further, triptans are not approved to be
taken during the aura phase because of their vasocon-
strictive properties. Third, it is of interest whether trip-
tans are efficacious against the headache in migraine
attacks both without and with aura when taken in the
headache phase. Since many patients have both types of
attacks, this refers to reliability of triptan efficacy. Beside
pain-free and abrupt relief from pain, this is a very import-
ant parameter for patients [6-8]. This is also expressed in* Correspondence: everss@uni-muenster.de
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reproduction in any medium, provided the origanother study, when 55% of the patients would prefer a
long-acting triptan versus a rapid-onset, short-acting agent
[9]. The very recent guideline of the International Headache
Society (IHS) for controlled trials of drugs in migraine de-
fined consistency as one of the secondary parameters for
the evaluation of results [10].
Frovatriptan is a potent 5-HT1B//D receptor agonist and
has the highest 5-HT1B potency in the triptan class; pre-
clinical pharmacodynamic studies demonstrated that fro-
vatriptan is apparently cerebroselective [11]. In clinical
pharmacology studies, frovatriptan was shown to have a
long terminal elimination half-life time of 26 hours
[11,12]. This could be an argument for better clinical
consistency. However, a direct comparison of frovatriptan
to different other triptans with respect to efficacy in mi-
graine attacks with aura is still missing.
Since frovatriptan has shown advantages in some out-
come parameters in a large study program comparing
frovatriptan to other triptans [13], we were interested in
whether this is also true when treating migraine attacksis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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those trials with a head-to-head comparison of frovatrip-
tan to another triptan in the acute treatment of migraine
attacks with aura. The aim of the study was to compare
the efficacy of the different triptans in the treatment of
these specific attacks with respect to headache. This ana-
lysis did not aim to evaluate the efficacy of triptans when
taken during the aura phase or the efficacy of triptans
against the aura symptoms.
Methods
This study is based on five trials which compared frova-
triptan to rizatriptan (two trials), zolmitriptan (two tri-
als), and almotriptan (one trial), respectively. All these
trials were double-blind, randomized crossover trials.
Three were Italian trials and already published [14-16].
Two were European trials not yet published as a full
paper (complete data on file). All trials were approved
by the local ethics committees. All patients gave written
informed consent before randomization.
The trial design of these five trials was nearly identical
and described previously [14-16]. In brief, patients aged
≥18 and ≤65 years with a current history of migraine
with or without aura according to the IHS criteria [17]
and having experienced an average of at least one but
not more than six migraine attacks per month for six
months prior to entry into the study were enrolled. Ex-
clusion criteria were a history suggestive of ischaemic
heart disease or any atherosclerotic disease indicating an
increased risk of coronary ischaemia; symptomatic car-
diac arrhythmias; history of stroke or transient ischaemic
attack (TIA); uncontrolled hypertension; history of basi-
lar, hemiplegic, or ophthalmoplegic migraine; severe liver
and renal impairment; renal disease, or renal failure;
known or suspected intolerance of, or hypersensitivity,
or contraindications to any component of the trial medica-
tions; use of either test medication to treat any one of the
last three episodes of migraine; history of intolerance or
inefficacy of at least two triptans for the treatment of mi-
graine attacks; abuse of alcohol, analgesics or psychotropic
drugs; any severe concurrent medical condition that, ac-
cording to the site investigator, may affect the interpret-
ation of clinical trial results; pregnancy or breastfeeding;
inability or unwillingness to issue the informed consent;
more than six days per month of tension-type headache.
Patients complying with these inclusion/exclusion cri-
teria were randomised 1 to 1 within each centre with a
predetermined randomisation list in balanced blocks, to
receive frovatriptan 2.5 mg or rizatriptan 10 mg, zolmi-
triptan 2.5 mg, and almotriptan 12.5 mg, respectively.
Prior to randomisation the patients were monitored for
migraine history including the MIDAS questionnaire,
medical history, medications history, vital signs. If ap-
plicable, a pregnancy test was performed.The assigned treatment was to be taken in three con-
secutive attacks of migraine. A patient could use up to
two doses two hours apart to treat an attack, and up to
two doses every 24 hours for episodes lasting more than
one day. The three episodes should occur in a period
not exceeding three months after randomisation. During
each episode, the patient recorded on a diary the inten-
sity of migraine pain from immediately before taking the
medication up to 48 hours. The patient also recorded
the use of medication, the possible relapse including
time of relapse, and any possible adverse event.
After having treated three episodes, the patient switched
to the alternative treatment, respectively, the other triptan
or frovatriptan 2.5 mg. On this occasion, adverse events
were reviewed, medication history checked and vital signs
monitored. The patient treated the subsequent three con-
secutive attacks of migraine with the treatment received
for the second period, with the same provisions as above
regarding the dosing. The three episodes should also occur
in a period not exceeding three months after switchover.
After having treated three episodes with the second medi-
cation, the patient concluded the study. On this occasion,
adverse events were reviewed, medication history checked,
and vital signs monitored.
In this post-hoc analysis, we included all attacks in
which an aura preceded the onset of the migraine head-
ache (i.e. before the intake of the study drug). Patients
were advised to take the study drug only when the mi-
graine headache was beginning and not during the aura.
However, it could be possible that the aura was still on-
going when the study drug was taken.
We evaluated the efficacy rate of the study drug for
pain free at 2/4/24/48 hours after drug intake as primary
endpoint; further we evaluated the mean headache in-
tensity according to a grading from 0 to 3 (0 = none; 1 =
mild; 2 =moderate; 3 = severe) and the 24 hour and
48 hour relapse rate. Statistical comparison among the
treatments was made between the combined results
from all five trials. Secondary endpoint was the mean
headache intensity at different time points which was
analysed by ANOVA. Percentages were compared using
Chi2-test. Significance level was set at p = 0.05.Results
The baseline characteristics including the MIDAS score
[18] of all study participants (intention-to-treat popula-
tion) who treated at least one migraine attack with aura
are presented in Table 1. The data are pooled according to
the comparative triptan. There were no significant differ-
ences in these demographic data between the five trials
analysed in this study. In total, 117 migraine attacks with
aura were included into this analysis (frovatriptan = 57;
rizatriptan = 28; zolmitriptan = 24; almotriptan = 8).
Table 1 Baseline characteristics of the patients included in this analysis (i.e., all patients experiencing an aura before
at least one attack treated with study drug) presented separately for the four different triptans
Rizatriptan Zolmitriptan Almotriptan Frovatriptan
(n = 28) (n = 24) (n = 8) (n = 57)
Age (years) 43 +/− 9 35 +/− 10 37 +/− 11 41 +/− 11
Females 89% 88% 100% 91%
MIDAS grade I 4% 0% 0% 4%
grade II 4% 0% 0% 6%
grade III 36% 55% 38% 43%
grade IV 57% 46% 63% 48%
Attack duration >2 days 46% 41% 63% 44%
Data are shown as mean (+/− SD), or frequency in %. There were no significant differences.
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not significantly different between the four triptan treat-
ments (Table 2). The 2 hour and 4 hour pain free rate
and the relapse rate for 24 hours and 48 hours are pre-
sented in Table 2. After 2 hours, more attacks were pain
free after frovatriptan as compared to rizatriptan. There
was a significantly lower percentage of relapse in attacks
with aura treated with frovatriptan than in attacks with
aura treated with the other triptans, both for the 24 and
48 hours endpoint (except for the comparison with
almotriptan at 48 hours).
In Figure 1, the mean headache intensity is presented
for the period covering 48 hours after intake of the study
drug. There was a significantly lower mean headache in-
tensity for frovatriptan at 4 hours as compared to all
other triptans and for frovatriptan and zolmitriptan at
48 hours as compared to rizatriptan and almotriptan
(but not between frovatriptan and zolmitriptan). We also
pooled the data from all comparative triptans. The meanTable 2 Pain free rate at 2 hours and headache recurrence ra
aura attacks
Rizatriptan zolmitript
(n = 28) (n = 24)
Baseline headache intensity1
mean 2.4 +/− 0.5 2.2 +/− 0.6
median 2 2
Pain free at
2 hours 10.7% 25.0%
4 hours 35.7% 50.0%
Recurrence at
24 hours 42.9% 37.5%
48 hours 89.3% 91.7%
1Headache intensity graded as 0 = none; 1 =mild; 2 =moderate; 3 = severe.
2p < 0.05 for comparison between frovatriptan and rizatriptan.
3only for comparison between frovatriptan and rizatriptan.
4post-hoc analysis: p = 0.025 for frovatriptan versus rizatriptan; p = 0.019 for frovatri
Data are shown as mean (+/− SD), or frequency in %. Statistical comparison by ANOheadache intensity after 2 hours was 1.2 +/− 1.0 for fro-
vatriptan and 1.6 +/− 1.0 for the other triptans (p <
0.05). After 4 hours, the mean headache intensity was
0.5 +/− 0.6 for frovatriptan and 1.2 +/− 1.1 for the other
triptans (p < 0.001).
When analyzing the adverse events, there were no sig-
nificant differences at all between the study drugs. The
number and types of adverse events were quite similar
to those seen in the migraine attacks without aura.
Discussion
Our data show that frovatriptan results in a significantly
lower relapse rate even when taken in acute migraine at-
tacks with aura as compared rizatriptan, zolmitriptan,
and almotriptan (the latter one not at 48 hours). This is
in concordance with a previous analysis of all migraine
attacks studied in a larger trial program [13]. Further-
more, this analysis confirms that triptans taken during
the headache phase are in general efficacious and wellte at 24 hours and 48 hours for all migraine with
an Almotriptan Frovatriptan Significance
(n = 8) (n = 57)
2.3 +/− 0.7 2.1 +/− 0.7 ns
2 2 ns
12.5% 29.8% p < 0.052
25.0% 50.9% ns
37.5% 26.3% p < 0.053
87.5% 66.7% p < 0.014
ptan versus zolmitriptan; p = 0.232 for frovatriptan versus almotriptan.
VA or Chi2-test (ns denotes not significant).
Figure 1 Mean headache intensity1 during attack treatment for all four different triptans. Statistical comparison by ANOVA, for post-hoc
analysis see text. 1Headache intensity graded as 0 = none; 1 =mild; 2 =moderate; 3 = severe.
Evers et al. The Journal of Headache and Pain  (2015) 16:28 Page 4 of 5tolerated in migraine with aura. This is of major import-
ance since many patients experience migraine attacks
both with and without aura; these patients do not have
to change their way of acute attack treatment (e.g., the
choice of a triptan) with respect to the aura.
The low recurrence rate of frovatriptan even in mi-
graine with aura is also of interest for many patients as
surveys on patients’ needs have shown [6,8]. In previous
trials, frovatriptan was able to decrease the overall dur-
ation of migraine attacks significantly [19], and it is more
efficacious when taken during the mild, beginning phase
of a migraine attack versus taken during the later severe
phase [20]. The short duration of attacks and the low re-
currence rate result in a significantly lower mean headache
intensity in this study after 24 hours and 48 hours. The
significantly lower relapse rate of frovatriptan can be ex-
plained by its pharmacological properties [21]. When
comparing all triptan trials, the elimination half-life time
is inversely correlated with the relapse rate (r = −1.0; p =
0.0016). Frovatriptan has by far the longest half-life time
(26 hours), whereas all the other oral triptans have a half-
life time between 2 and 6 hours.
Some of our findings are surprising with respect to the
literature, in particular the good efficacy of frovatriptan
after 2 and 4 hours as compared to rizatriptan. The
baseline characteristics of the migraine attacks and the
MIDAS scores show that patients with mainly severe
and long-lasting migraine attacks were enrolled into this
study program. This might be the reason why frovatrip-
tan, which is normally less efficacious in the first 2 hours
after drug intake, was of particular efficacy in this study.A limitation of this study is that it is a metaanalysis
of different trials which were not designed to study the
efficacy in migraine with aura as their primary end-
point. However, this metaanalysis is justified, since
these trials all had a nearly identical design and since
the two hour pain free rates in general were not signifi-
cantly different between these triptans [13], i.e. the
2 hour pain free rate was not significantly lower for
frovatriptan than for rizatriptan, zolmitriptan, or almo-
triptan. Previous analyses had suggested that the two
hour pain free rate for frovatriptan is lower than for
other triptans [11]; however, this has been shown in
trials with treatment at any time during the migraine
attack. When reevaluating this aforementioned finding
in migraine attacks treated early, there was no signifi-
cant difference between frovatriptan and other triptans
regarding 2 hour pain free rates [11,22]. Also in the tri-
als analysed here, patients were advised to treat their
migraine attacks early.
Another limitation is that we did not extend our com-
parison to the remaining triptans (sumatriptan, naratrip-
tan, eletriptan) or to other acute migraine drugs such as
NSAIDs or ergotamine derivatives. Thus, the final pos-
ition of frovatriptan within all acute migraine drugs with
respect to efficacy in migraine with aura cannot be de-
termined by this study.
Finally, the number of patients/attacks with aura was
quite different between the different treatment groups.
In particular, the comparison to almotriptan with only 8
attacks included in this analysis is problematic due to
statistical reasons (large confidence intervals etc.).
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In summary, frovatriptan provides an efficacious treat-
ment for migraine attacks with aura when taken during
the headache phase with respect to acute efficacy and
to relapse.
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